IMPLANET Announces Its 2024 Financial Calendar
11 Janvier 2024 - 6:00PM
Business Wire
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for
PEA-PME equity savings plans), a medical technology company
specializing in implants for orthopedic surgery and the
distribution of technological medical equipment, today announces
its schedule for the publication of financial information for
2024Etats-Unis de son expansion commerciale aux Etats-Unis,.
Event
Dates*
2023 Full-Year Revenue
January 15, 2024
2023 Full-Year Results
March 5, 2024
2024 First-Quarter Revenue
April 9, 2024
Annual General Meeting
April 25, 2024
2024 First-Half Revenue
July 9, 2024
2024 First-Half Results
September 10, 2024
2024 Third-Quarter Revenue
October 8, 2024
(*) Subject to change. Press releases will be issued after
market close.
Upcoming financial
publication
- 2023 Full-Year Revenue, on January 15, 2024 after
market
About IMPLANET Founded in 2007, IMPLANET is a medical
technology company that manufactures high-quality implants for
orthopedic surgery and distributing medical technology equipment.
Its activity revolves around a comprehensive innovative solution
for improving the treatment of spinal pathologies (JAZZ®)
complemented by the product range offered by Orthopaedic &
Spine Development (OSD), acquired in May 2021 (thoraco-lumbar
screws, cages and cervical plates). Implanet’s tried-and-tested
orthopedic platform is based on the traceability of its products.
Protected by four families of international patents, JAZZ® has
obtained 510(k) regulatory clearance from the Food and Drug
Administration (FDA) in the United States, the CE mark in Europe
and ANVISA approval in Brazil. In 2022, IMPLANET entered into a
commercial, technological and financial partnership with SANYOU
MEDICAL, China's second largest medical device manufacturer.
IMPLANET employs 43 staff and recorded a consolidated revenue of
€8.0 million in 2022. Based near Bordeaux in France, IMPLANET
opened a US subsidiary in Boston in 2013. IMPLANET is listed on the
Euronext Growth market in Paris. For further information, please
visit www.Implanet.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111331422/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin Nicolas Fossiez
Tél.: +33 (0)1 44 71 94 94 Implanet@newcap.eu
NewCap Media Relations Arthur Rouillé Tél.: +33 (0)1 44
71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024